Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cost-Benefit Analysis | 46 | 2024 | 5491 | 3.370 |
Why?
|
Quality-Adjusted Life Years | 24 | 2023 | 1722 | 2.440 |
Why?
|
Models, Economic | 10 | 2020 | 716 | 1.960 |
Why?
|
Carotid Stenosis | 10 | 2020 | 860 | 1.750 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2021 | 3243 | 1.420 |
Why?
|
Health Care Costs | 8 | 2022 | 3240 | 1.250 |
Why?
|
Cardiovascular Diseases | 21 | 2023 | 15476 | 1.110 |
Why?
|
Reimbursement, Incentive | 2 | 2020 | 540 | 0.920 |
Why?
|
Budgets | 2 | 2022 | 229 | 0.850 |
Why?
|
Judgment | 1 | 2023 | 273 | 0.740 |
Why?
|
Stroke | 15 | 2024 | 9745 | 0.690 |
Why?
|
Fibrinolytic Agents | 2 | 2020 | 2082 | 0.640 |
Why?
|
Physician Incentive Plans | 1 | 2020 | 164 | 0.640 |
Why?
|
Life Expectancy | 6 | 2023 | 1240 | 0.630 |
Why?
|
Anemia, Sickle Cell | 2 | 2024 | 1063 | 0.600 |
Why?
|
Plaque, Atherosclerotic | 6 | 2020 | 1524 | 0.590 |
Why?
|
Ultrasonography, Doppler | 1 | 2019 | 461 | 0.570 |
Why?
|
Brain Ischemia | 6 | 2022 | 3048 | 0.550 |
Why?
|
Epidemics | 5 | 2021 | 512 | 0.510 |
Why?
|
Drug Costs | 4 | 2022 | 1179 | 0.510 |
Why?
|
Immunoconjugates | 1 | 2022 | 953 | 0.490 |
Why?
|
Periodontitis | 1 | 2019 | 559 | 0.480 |
Why?
|
Diabetic Angiopathies | 1 | 2019 | 804 | 0.470 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2020 | 628 | 0.470 |
Why?
|
Quality Indicators, Health Care | 2 | 2024 | 1792 | 0.460 |
Why?
|
Hyperlipidemias | 1 | 2018 | 771 | 0.440 |
Why?
|
Primary Prevention | 3 | 2018 | 1186 | 0.430 |
Why?
|
Cholesterol, LDL | 2 | 2021 | 2379 | 0.420 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 1405 | 0.410 |
Why?
|
Cardiology | 1 | 2023 | 1668 | 0.410 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2023 | 2117 | 0.400 |
Why?
|
Thrombolytic Therapy | 2 | 2020 | 2061 | 0.390 |
Why?
|
Practice Guidelines as Topic | 3 | 2020 | 7380 | 0.380 |
Why?
|
Vascular Diseases | 1 | 2019 | 1161 | 0.380 |
Why?
|
Tissue Plasminogen Activator | 1 | 2017 | 1163 | 0.380 |
Why?
|
Nutrition Surveys | 5 | 2019 | 1726 | 0.370 |
Why?
|
United States | 29 | 2024 | 72202 | 0.360 |
Why?
|
Finger Injuries | 1 | 2011 | 145 | 0.340 |
Why?
|
Humans | 86 | 2024 | 760437 | 0.330 |
Why?
|
Atherosclerosis | 2 | 2015 | 3407 | 0.330 |
Why?
|
Nails | 1 | 2011 | 295 | 0.330 |
Why?
|
Risk Assessment | 11 | 2019 | 23953 | 0.320 |
Why?
|
Coronary Vessels | 1 | 2020 | 3088 | 0.320 |
Why?
|
Computer Simulation | 8 | 2022 | 6230 | 0.310 |
Why?
|
Motivation | 1 | 2018 | 2006 | 0.310 |
Why?
|
Preventive Medicine | 2 | 2020 | 246 | 0.310 |
Why?
|
Decision Support Systems, Clinical | 1 | 2017 | 1172 | 0.290 |
Why?
|
Models, Neurological | 1 | 2016 | 1765 | 0.290 |
Why?
|
Thrombectomy | 3 | 2022 | 704 | 0.290 |
Why?
|
Laboratories | 1 | 2011 | 462 | 0.290 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2023 | 12127 | 0.290 |
Why?
|
Quality Improvement | 2 | 2020 | 3798 | 0.290 |
Why?
|
Coronary Artery Disease | 3 | 2022 | 6388 | 0.290 |
Why?
|
Calcium | 1 | 2020 | 5726 | 0.280 |
Why?
|
Psychotic Disorders | 1 | 2022 | 3208 | 0.270 |
Why?
|
Pulmonary Embolism | 1 | 2020 | 2563 | 0.270 |
Why?
|
Cities | 7 | 2022 | 543 | 0.270 |
Why?
|
Mass Screening | 4 | 2015 | 5424 | 0.260 |
Why?
|
Ischemic Attack, Transient | 3 | 2024 | 878 | 0.260 |
Why?
|
Aged | 29 | 2021 | 168840 | 0.250 |
Why?
|
Asymptomatic Diseases | 3 | 2019 | 587 | 0.250 |
Why?
|
Middle Aged | 35 | 2021 | 220382 | 0.250 |
Why?
|
Drug Combinations | 2 | 2023 | 2043 | 0.250 |
Why?
|
Aged, 80 and over | 15 | 2021 | 58859 | 0.240 |
Why?
|
HIV Infections | 8 | 2023 | 17328 | 0.240 |
Why?
|
Cerebrovascular Circulation | 1 | 2014 | 2728 | 0.230 |
Why?
|
Markov Chains | 5 | 2017 | 965 | 0.220 |
Why?
|
Fluorides | 1 | 2024 | 134 | 0.210 |
Why?
|
Male | 37 | 2024 | 360035 | 0.210 |
Why?
|
Burns | 2 | 2012 | 1863 | 0.210 |
Why?
|
Heart Failure | 3 | 2023 | 11653 | 0.210 |
Why?
|
Chest Pain | 2 | 2020 | 1090 | 0.210 |
Why?
|
Delivery of Health Care | 2 | 2018 | 5332 | 0.200 |
Why?
|
Surgical Flaps | 1 | 2011 | 1669 | 0.200 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2024 | 147 | 0.200 |
Why?
|
Primary Health Care | 1 | 2018 | 4674 | 0.190 |
Why?
|
Gross Domestic Product | 1 | 2022 | 78 | 0.190 |
Why?
|
Female | 38 | 2024 | 391875 | 0.190 |
Why?
|
Models, Theoretical | 3 | 2020 | 3576 | 0.190 |
Why?
|
Decision Support Techniques | 3 | 2024 | 1998 | 0.190 |
Why?
|
Diagnostic Imaging | 1 | 2015 | 3541 | 0.190 |
Why?
|
Itraconazole | 2 | 2012 | 43 | 0.180 |
Why?
|
Antibodies, Bispecific | 1 | 2023 | 196 | 0.180 |
Why?
|
Coronary Angiography | 3 | 2022 | 4468 | 0.180 |
Why?
|
Quality of Life | 4 | 2020 | 13338 | 0.170 |
Why?
|
Fluconazole | 2 | 2012 | 156 | 0.170 |
Why?
|
Decision Making, Organizational | 1 | 2020 | 136 | 0.170 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2023 | 1240 | 0.170 |
Why?
|
Hemophilia A | 1 | 2023 | 360 | 0.170 |
Why?
|
Immunization, Secondary | 1 | 2021 | 368 | 0.160 |
Why?
|
American Heart Association | 1 | 2023 | 1045 | 0.160 |
Why?
|
Policy | 1 | 2022 | 508 | 0.150 |
Why?
|
Adult | 24 | 2023 | 220781 | 0.150 |
Why?
|
Cost Savings | 4 | 2019 | 913 | 0.150 |
Why?
|
Sodium | 1 | 2023 | 1589 | 0.150 |
Why?
|
Myocardial Perfusion Imaging | 2 | 2020 | 570 | 0.140 |
Why?
|
Mycoses | 2 | 2012 | 386 | 0.140 |
Why?
|
Tetrazoles | 1 | 2023 | 907 | 0.140 |
Why?
|
Algorithms | 5 | 2024 | 14002 | 0.140 |
Why?
|
Heptanoic Acids | 2 | 2009 | 344 | 0.140 |
Why?
|
Decision Making | 4 | 2023 | 3923 | 0.140 |
Why?
|
Comparative Effectiveness Research | 2 | 2019 | 708 | 0.140 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2023 | 1031 | 0.140 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 1517 | 0.130 |
Why?
|
Urban Population | 2 | 2021 | 2032 | 0.130 |
Why?
|
Cholesterol | 3 | 2016 | 2902 | 0.130 |
Why?
|
Substance Abuse, Intravenous | 1 | 2020 | 530 | 0.130 |
Why?
|
Risk Factors | 10 | 2020 | 74055 | 0.130 |
Why?
|
Cost of Illness | 2 | 2022 | 1931 | 0.130 |
Why?
|
Amyloidosis | 1 | 2022 | 817 | 0.130 |
Why?
|
Antifungal Agents | 2 | 2012 | 751 | 0.130 |
Why?
|
Treatment Outcome | 8 | 2022 | 64591 | 0.120 |
Why?
|
Secondary Prevention | 2 | 2019 | 1474 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2020 | 10180 | 0.120 |
Why?
|
Cerebral Revascularization | 1 | 2016 | 258 | 0.110 |
Why?
|
Brain Infarction | 1 | 2016 | 290 | 0.110 |
Why?
|
Babesia microti | 1 | 2013 | 31 | 0.110 |
Why?
|
Antihypertensive Agents | 1 | 2023 | 2018 | 0.110 |
Why?
|
Endarterectomy, Carotid | 2 | 2016 | 555 | 0.110 |
Why?
|
Time Factors | 7 | 2020 | 39947 | 0.110 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2022 | 2199 | 0.110 |
Why?
|
Kerosene | 1 | 2012 | 15 | 0.100 |
Why?
|
Babesiosis | 1 | 2013 | 92 | 0.100 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2019 | 1047 | 0.100 |
Why?
|
Pyrroles | 2 | 2009 | 1126 | 0.100 |
Why?
|
Calibration | 4 | 2019 | 818 | 0.100 |
Why?
|
Incidence | 5 | 2022 | 21322 | 0.100 |
Why?
|
Information Dissemination | 1 | 2020 | 1127 | 0.100 |
Why?
|
ROC Curve | 2 | 2017 | 3571 | 0.100 |
Why?
|
Weight Loss | 1 | 2023 | 2683 | 0.100 |
Why?
|
Probability | 1 | 2017 | 2476 | 0.100 |
Why?
|
Magnetic Resonance Imaging | 3 | 2020 | 36362 | 0.100 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2022 | 3765 | 0.100 |
Why?
|
Blood Donors | 1 | 2013 | 345 | 0.100 |
Why?
|
Coronary Disease | 2 | 2020 | 5919 | 0.100 |
Why?
|
Glucose | 1 | 2023 | 4342 | 0.090 |
Why?
|
Data Collection | 1 | 2020 | 3321 | 0.090 |
Why?
|
Mental Health Services | 1 | 2023 | 1730 | 0.090 |
Why?
|
Rural Population | 1 | 2021 | 2279 | 0.090 |
Why?
|
Cardiomyopathies | 1 | 2022 | 1957 | 0.090 |
Why?
|
Population Surveillance | 3 | 2019 | 2603 | 0.090 |
Why?
|
Socioeconomic Factors | 2 | 2022 | 7817 | 0.090 |
Why?
|
Contracture | 1 | 2012 | 235 | 0.080 |
Why?
|
South Africa | 4 | 2016 | 1840 | 0.080 |
Why?
|
Risk Reduction Behavior | 1 | 2016 | 1112 | 0.080 |
Why?
|
Stroke Volume | 1 | 2023 | 5487 | 0.080 |
Why?
|
Skin Transplantation | 2 | 2012 | 1083 | 0.080 |
Why?
|
Bayes Theorem | 1 | 2017 | 2326 | 0.080 |
Why?
|
Parents | 1 | 2022 | 3563 | 0.080 |
Why?
|
Dyslipidemias | 1 | 2016 | 868 | 0.080 |
Why?
|
Predictive Value of Tests | 2 | 2022 | 15257 | 0.080 |
Why?
|
Endovascular Procedures | 1 | 2022 | 2179 | 0.080 |
Why?
|
Cerebral Angiography | 1 | 2014 | 1281 | 0.080 |
Why?
|
Uterine Cervical Neoplasms | 2 | 2011 | 2016 | 0.080 |
Why?
|
Magnetic Resonance Angiography | 1 | 2015 | 1433 | 0.080 |
Why?
|
Models, Statistical | 6 | 2020 | 5078 | 0.070 |
Why?
|
Disease Management | 1 | 2018 | 2501 | 0.070 |
Why?
|
Dementia | 1 | 2022 | 2679 | 0.070 |
Why?
|
Retrospective Studies | 6 | 2024 | 80430 | 0.070 |
Why?
|
Cause of Death | 1 | 2017 | 3686 | 0.070 |
Why?
|
Survival Analysis | 2 | 2017 | 10075 | 0.070 |
Why?
|
Registries | 1 | 2022 | 8216 | 0.060 |
Why?
|
Drug Prescriptions | 1 | 2015 | 1669 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9176 | 0.060 |
Why?
|
Hypolipidemic Agents | 1 | 2010 | 609 | 0.060 |
Why?
|
Health Policy | 1 | 2017 | 2680 | 0.060 |
Why?
|
Patient-Centered Care | 1 | 2015 | 1416 | 0.060 |
Why?
|
Ultrasonography | 2 | 2014 | 5966 | 0.060 |
Why?
|
Anticoagulants | 1 | 2020 | 4806 | 0.060 |
Why?
|
Life Style | 1 | 2016 | 3909 | 0.060 |
Why?
|
HIV | 2 | 2022 | 1582 | 0.060 |
Why?
|
Neutropenia | 1 | 2009 | 884 | 0.060 |
Why?
|
Mammography | 1 | 2015 | 2426 | 0.060 |
Why?
|
Cross-Sectional Studies | 6 | 2016 | 26063 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5421 | 0.050 |
Why?
|
Health Surveys | 1 | 2013 | 4056 | 0.050 |
Why?
|
Risk | 1 | 2015 | 9605 | 0.050 |
Why?
|
Software | 1 | 2017 | 4426 | 0.050 |
Why?
|
Diphosphates | 1 | 2022 | 84 | 0.050 |
Why?
|
Technetium | 1 | 2022 | 322 | 0.050 |
Why?
|
Smoking | 2 | 2016 | 9046 | 0.050 |
Why?
|
Economics | 1 | 2023 | 141 | 0.050 |
Why?
|
Referral and Consultation | 1 | 2015 | 3596 | 0.050 |
Why?
|
Child | 4 | 2024 | 80086 | 0.050 |
Why?
|
Anticholesteremic Agents | 1 | 2008 | 966 | 0.050 |
Why?
|
Factor VIII | 1 | 2023 | 349 | 0.050 |
Why?
|
Prealbumin | 1 | 2022 | 222 | 0.050 |
Why?
|
Age Distribution | 2 | 2020 | 2878 | 0.050 |
Why?
|
Early Detection of Cancer | 1 | 2015 | 3183 | 0.040 |
Why?
|
Europe | 2 | 2022 | 3419 | 0.040 |
Why?
|
Adolescent | 8 | 2024 | 88196 | 0.040 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2024 | 2750 | 0.040 |
Why?
|
Health Status Disparities | 2 | 2021 | 1847 | 0.040 |
Why?
|
New York City | 1 | 2021 | 730 | 0.040 |
Why?
|
Atenolol | 1 | 2019 | 99 | 0.040 |
Why?
|
Cohort Studies | 5 | 2024 | 41366 | 0.040 |
Why?
|
Drug Users | 1 | 2020 | 134 | 0.040 |
Why?
|
Young Adult | 7 | 2021 | 59068 | 0.040 |
Why?
|
Ramipril | 1 | 2019 | 102 | 0.040 |
Why?
|
Disease Progression | 1 | 2015 | 13484 | 0.040 |
Why?
|
Sexuality | 1 | 2019 | 179 | 0.040 |
Why?
|
Selection Bias | 1 | 2019 | 359 | 0.040 |
Why?
|
Developing Countries | 3 | 2015 | 2882 | 0.040 |
Why?
|
Costs and Cost Analysis | 1 | 2023 | 1668 | 0.040 |
Why?
|
Health Plan Implementation | 1 | 2020 | 337 | 0.040 |
Why?
|
Diabetes Mellitus | 1 | 2016 | 5835 | 0.040 |
Why?
|
India | 2 | 2016 | 2341 | 0.040 |
Why?
|
Blood Transfusion | 1 | 2024 | 1299 | 0.040 |
Why?
|
Insurance Claim Review | 1 | 2021 | 735 | 0.030 |
Why?
|
Carotid Arteries | 1 | 2020 | 941 | 0.030 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2020 | 319 | 0.030 |
Why?
|
Opiate Substitution Treatment | 1 | 2020 | 443 | 0.030 |
Why?
|
South America | 1 | 2016 | 179 | 0.030 |
Why?
|
Hypertension | 1 | 2016 | 8527 | 0.030 |
Why?
|
Medication Adherence | 2 | 2019 | 2166 | 0.030 |
Why?
|
Uncertainty | 1 | 2020 | 753 | 0.030 |
Why?
|
Blood Pressure | 1 | 2011 | 8479 | 0.030 |
Why?
|
Homosexuality, Male | 1 | 2023 | 1333 | 0.030 |
Why?
|
Angiography | 1 | 2020 | 1599 | 0.030 |
Why?
|
Pakistan | 1 | 2016 | 293 | 0.030 |
Why?
|
Guatemala | 1 | 2015 | 159 | 0.030 |
Why?
|
Continuity of Patient Care | 1 | 2022 | 1069 | 0.030 |
Why?
|
Renin-Angiotensin System | 1 | 2019 | 737 | 0.030 |
Why?
|
Erythrocytes | 1 | 2024 | 2417 | 0.030 |
Why?
|
Sex Factors | 2 | 2019 | 10538 | 0.030 |
Why?
|
Likelihood Functions | 1 | 2017 | 990 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2019 | 2569 | 0.030 |
Why?
|
Policy Making | 1 | 2017 | 540 | 0.030 |
Why?
|
Models, Biological | 1 | 2010 | 9462 | 0.030 |
Why?
|
Infant | 3 | 2024 | 36183 | 0.030 |
Why?
|
Kenya | 1 | 2016 | 757 | 0.030 |
Why?
|
Mexico | 1 | 2015 | 761 | 0.030 |
Why?
|
Endemic Diseases | 1 | 2013 | 190 | 0.030 |
Why?
|
Child, Preschool | 3 | 2024 | 42209 | 0.030 |
Why?
|
Yoga | 1 | 2016 | 281 | 0.030 |
Why?
|
Burns, Chemical | 1 | 2012 | 122 | 0.020 |
Why?
|
Hemorrhage | 1 | 2023 | 3414 | 0.020 |
Why?
|
Patient Transfer | 1 | 2018 | 793 | 0.020 |
Why?
|
China | 1 | 2016 | 2339 | 0.020 |
Why?
|
Economics, Pharmaceutical | 1 | 2010 | 87 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 2016 | 1814 | 0.020 |
Why?
|
Life Tables | 1 | 2009 | 365 | 0.020 |
Why?
|
Neck | 1 | 2014 | 735 | 0.020 |
Why?
|
Necrosis | 1 | 2013 | 1604 | 0.020 |
Why?
|
Diet, Mediterranean | 1 | 2016 | 742 | 0.020 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2020 | 2788 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2019 | 20078 | 0.020 |
Why?
|
Models, Econometric | 1 | 2009 | 216 | 0.020 |
Why?
|
Injury Severity Score | 1 | 2012 | 1045 | 0.020 |
Why?
|
Mortality | 1 | 2019 | 2897 | 0.020 |
Why?
|
Carotid Artery Diseases | 1 | 2014 | 872 | 0.020 |
Why?
|
Disease Transmission, Infectious | 1 | 2013 | 557 | 0.020 |
Why?
|
Patient Discharge | 1 | 2021 | 3436 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2020 | 3685 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2015 | 20985 | 0.020 |
Why?
|
Aspirin | 1 | 2019 | 3134 | 0.020 |
Why?
|
Forecasting | 1 | 2016 | 2925 | 0.020 |
Why?
|
Public Health | 1 | 2020 | 2665 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2009 | 10759 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10494 | 0.020 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2010 | 384 | 0.020 |
Why?
|
Needs Assessment | 1 | 2012 | 1139 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2020 | 3344 | 0.020 |
Why?
|
Disability Evaluation | 1 | 2012 | 1834 | 0.010 |
Why?
|
Hospitals | 1 | 2018 | 3873 | 0.010 |
Why?
|
Regression Analysis | 1 | 2014 | 6340 | 0.010 |
Why?
|
Smoking Cessation | 1 | 2016 | 2053 | 0.010 |
Why?
|
Patient Selection | 1 | 2016 | 4240 | 0.010 |
Why?
|
Canada | 1 | 2009 | 2119 | 0.010 |
Why?
|
Health Services Research | 1 | 2011 | 1811 | 0.010 |
Why?
|
Research Design | 1 | 2019 | 6168 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2024 | 26280 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 7996 | 0.010 |
Why?
|
Prevalence | 1 | 2020 | 15698 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2012 | 4808 | 0.010 |
Why?
|
Lipids | 1 | 2013 | 3342 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2013 | 39078 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 2 | 2015 | 20551 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8623 | 0.010 |
Why?
|
Stress, Psychological | 1 | 2016 | 4475 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2015 | 14661 | 0.010 |
Why?
|
Exercise | 1 | 2016 | 5874 | 0.010 |
Why?
|
Age Factors | 1 | 2016 | 18379 | 0.010 |
Why?
|
Graft vs Host Disease | 1 | 2012 | 3028 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2013 | 12429 | 0.010 |
Why?
|
Body Mass Index | 1 | 2016 | 12932 | 0.010 |
Why?
|
Diet | 1 | 2016 | 8058 | 0.010 |
Why?
|
Papillomavirus Infections | 1 | 2010 | 1610 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2014 | 8967 | 0.010 |
Why?
|
Prognosis | 1 | 2016 | 29551 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2010 | 11096 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2011 | 14565 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15820 | 0.010 |
Why?
|
Prospective Studies | 1 | 2014 | 54339 | 0.010 |
Why?
|